The morning's news flow is dominated by a landmark private equity deal in UK healthcare, alongside a run of upbeat trading updates spanning rental housing, emerging markets asset management and semiconductor manufacturing. Corporate confidence runs through the tape, with guidance upgrades from The Works and Standard Life sitting alongside a significant US regulatory approval for AstraZeneca.
Spire Healthcare agrees £1.03bn takeover by Toscafund-led consortium
Spire Healthcare Group (LSE:SPI) has agreed to a recommended cash takeover by Tulip UK Bidco, a vehicle backed by a consortium including Toscafund Asset Management, THCP Advisory (Three Hills) and Ares Management. The 250p per share offer values Spire's entire issued share capital at approximately £1,026.5m and implies an enterprise value of around £2,307.6m, marking one of the largest UK healthcare buyouts in years. Spire operates 38 hospitals and more than 55 clinics across England, Wales and Scotland, treating over 1.36m patients in 2025 and holding the largest UK market share by volume in knee and hip operations.
The offer price represents a premium of 66.2% to Spire's closing price on 13 May, the day before the possible offer was first flagged, and equates to 8.6 times the company's adjusted EBITDA for the year ended 31 December 2025. Eligible shareholders can alternatively roll some or all of their holdings into unlisted loan notes exchangeable for shares in the acquirer's parent, capped at 28m Spire shares, though the board is not recommending this route and none of the directors intend to take it up. Rothschild & Co approached more than 60 potential acquirers over eight months following Spire's September 2025 strategic review, with Tulip the only party to table a proposal the board judged attractive enough to pursue. Shareholders holding approximately 53.4% of Spire's issued share capital, including Mediclinic Jersey, Harwood Capital Management and Richard Griffiths, have given irrevocable undertakings to support the deal.
"The Cash Offer of 250p per share was higher than all other formal proposals received during this process, and provides certain value in cash today for Spire Shareholders," said Richard Griffiths, Chair.
The transaction removes Spire from public markets at a moment when private capital continues to see structural value in UK hospital infrastructure that listed valuations have struggled to reflect. With over half the register already locked in, the path to completion looks clear, though the deal still needs shareholder votes, court sanction and FCA approval of the change of control before it can close, expected in the fourth quarter of 2026 or first quarter of 2027. For the wider private hospital sector, the price tag sets a fresh benchmark for what scale, market share and elective-procedure volume are worth to buyers hunting for defensive, cash-generative healthcare assets.
Grainger reaffirms guidance as rental growth edges up
Grainger (LSE:GRI) told investors that trading for the eleven months to the end of August remained in line with guidance, with like-for-like Build to Rent rental growth of 3%, up from 2.9% at the half-year stage in March. The UK's largest listed provider of private rental homes, which manages over 11,000 rental properties, reported occupancy holding steady above 96%, while leasing at its newest scheme, Glasshouse Square in Bristol, is running ahead of expectations with 313 of 374 homes let or under offer nine months after its November 2025 launch.
Chief executive Helen Gordon said the group remains on track to grow earnings by 35% from FY25 to FY29 from build-to-rent development projects in its committed pipeline, and is targeting net debt reduction of £300-350m by the end of FY29. Grainger also secured planning permission for a 425-home scheme in Cambridge, its first investment in the city, developed jointly with Network Rail's Platform4 and blocwork.
The reaffirmed guidance and steady occupancy signal that Grainger's rental growth trajectory has held up even as broader UK housing demand remains uneven, reinforcing the case for its development pipeline as the primary earnings driver into the end of the decade. The Cambridge entry also extends Grainger's geographic footprint into a new university city, adding a fresh growth market alongside its existing regional concentration.
Ashmore profit jumps as emerging market inflows return
Ashmore Group (LSE:ASHM), the specialist emerging markets asset manager, reported assets under management rose 13% to $54.0bn for the year ended 30 June, driven by net inflows of $2.7bn and $3.7bn of investment performance gains. Gross subscriptions increased 92% to $12.5bn while redemptions fell 20% to $9.8bn, evidence that investor appetite for emerging market debt and equities has turned a corner.
Adjusted net revenue fell 7% to £135.6m on lower performance fees, but an £82.5m gain on the group's seed capital programme helped lift profit before tax 17% to £126.9m, with diluted earnings per share up 28% to 15.0p. The board maintained the final ordinary dividend at 12.1p, taking total dividends per share to 16.9p, backed by more than £600m of financial resources and excess capital of 73p per share. Equities now account for 19% of group AuM, while local office AuM grew 13%, led by Colombia, Indonesia and India. "Ashmore's diversified global platform and focused emerging markets strategy delivered meaningful growth in AuM and profits during the year," said Mark Coombs, chief executive.
The reversal in net flows after a prolonged period of redemptions across the emerging markets fund sector marks a notable inflection point for Ashmore, suggesting the group's diversified local-currency and hard-currency strategies are regaining favour as investors rotate back toward EM risk.
IQE revenue jumps, profitability swings positive
IQE (AIM:IQE), the AIM-listed supplier of compound semiconductor wafer products, reported first-half revenue of £64.6m, up 43% year-on-year from £45.3m, with adjusted EBITDA turning positive at £6m compared with a £0.4m loss a year earlier. The Cardiff-based group's photonics division led the recovery, with revenue up 45% to £38.5m on funding releases for US military and defence programmes and continued growth in AI and data centre markets, while wireless revenue rose 40% to £26m on market share gains and new customer platform qualifications.
Cash and cash equivalents stood at £41.6m at 30 June, with the group moving to an adjusted net cash position of £30.2m, a reversal from adjusted net debt of £23.5m a year earlier, following its strategic review and fundraising proceeds. Reported net cashflow from operations was £1.2m, down from £3.6m, after a £4m working capital outflow and £2.4m of restructuring and strategic review costs. "I am pleased to report a strong first half performance, with more than 40% revenue growth year-on-year across our core markets driving profitability," said Jutta Meier, chief executive.
The swing to positive EBITDA and net cash marks a turning point for a company that spent recent years working through balance sheet strain, and positions IQE to capitalise on defence and AI-driven demand for compound semiconductor wafers without the immediate pressure of refinancing risk.
The Works lifts FY27 profit guidance on strong sales growth
The Works (WRKS) raised its full-year earnings guidance after like-for-like sales jumped 10.4% in the first 18 weeks of the financial year, a marked acceleration for the crafts and stationery retailer.
The upgrade points to stronger-than-expected consumer demand for the group's arts, crafts and gifting ranges heading into the key autumn and Christmas trading period, giving management confidence to lift its profit outlook for the full year.
Standard Life lifts operating profit 25% in first half
Standard Life (SDLF) confirmed it remains on track to meet its end-2026 financial targets after operating profit rose 25% in the first half, as the retirement savings group prepares to complete its £2bn acquisition of Aegon UK.
The profit growth and reaffirmed targets underline the scale benefits management expects once the Aegon UK deal completes, consolidating Standard Life's position in the UK retirement savings and workplace pensions market.
AstraZeneca wins US approval for Etcamah in breast cancer
AstraZeneca (LSE:AZN) secured FDA clearance for its oral SERD Etcamah, to be paired with a CDK4/6 inhibitor, for HR-positive breast cancer patients who develop a resistance mutation before their disease progresses.
The approval extends AstraZeneca's oncology portfolio into a new treatment window, giving clinicians an option to intervene against resistance mutations earlier in the treatment course rather than waiting for confirmed disease progression, a shift that could broaden the drug's addressable patient population.
